An observational study in Neuromuscular Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 3 under way, none of them phase 3. Neuromuscular Diseases · Assistance Publique - Hôpitaux de Paris.
Among the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2025, is one of 6 observational ones, and was the 8th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →3 of the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 0–17
By country, each count listing its studies:
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 368 is above the median of 72 across 144 observational studies indexed under Neuromuscular Diseases.
Median enrollment 24 across the 4 interventional studies, 89 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Neuromuscular Diseases by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Development and validation study of a prognostic score - study of prognostic performance by a prospective longitudinal multicenter cohort spread over 8 centers: 4 for the development cohort and 4 for the validation cohort).
Progressive muscle weakness in neuromuscular diseases leads to motor disabilities leading to permanentfull-time wheelchair use. This is the case for infantile spinal muscular atrophy type II (SMA II), where people are dependent on a permanent sitting position from early childhood, at 2 years of age, or for Duchenne muscular dystrophy, when they lose their ability to walk around 10 years without corticosteroid therapy or around 13 years with treatment. These wheelchair users, weakened by the disease, are subject to musculotendinous retractions, osteo-articular stiffness, spinal deformities and pain. In addition, they use the wheelchair on a daily basis, on average 12 hours a day, whose permanent sitting position also conditions the performance of achieving life habits.
The analysis of the static and dynamic seated postural installation in the wheelchair makes it possible to avoid harmful consequences on the health and quality of life of users on a daily basis. When performed early enough, regularly and optimally, it also contributes to the prevention of complications.
In France, these assessments are carried out by occupational therapists, accompanied by doctors of Physical Medicine and Rehabilitation.
The weakness of the literature in this area and the absence of recommendations do not allow the user or any health professional to identify the need and the level of urgency to benefit from a dedicated consultation.
Faced with this observation, the development of a prognostic score for a change in positioning in the wheelchair, based on a prospective multicenter cohort and its validation on an external prospective cohort, will allow any healthcare professional to guide the user to a necessary positioning consultation. The hypothesis is that this score has discriminating qualities and that it is calibrated to predict a change in the seat of the RF and therefore the need to reassess the seated postural installation.
Having a neuromuscular disease such as Duchenne Muscular Dystrophy or Infantile Spinal Muscular Atrophy type II.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neuromuscular diseases
Other: usual care
Neuromuscular diseases
Other: usual care
For each cohort, the patient is seen at least twice, during annual visits in multidisciplinary consultation.
Change in the seating system of the user's wheelchair
Any change in the seating system of the user's wheelchair within 12 months will be noted. A change in the seating system is defined by the occurrence of at least one of these situations: * one or more seat/back adjustments: depth, width, height * addition/removal of postural elements * replacement of the cushion, or backrest or headrest * Use of electric functions of the wheelchair or on-board standing * modification of control device of the WC.
Time frame: through study completion, to 12 months
Seated Postural Control Measure (SPCM)
Seated Postural Control Measure (SPCM) is an instrument for the clinical assessment of seated postural control in adult clients using a locomotion aid. It therefore allows the evaluation of the two variables in inherent to postural control seated, i.e. the alignment of body segments and the influence between movement and posture. It also helps to assess changes of seated postural control due to the evolution over time or to an intervention of a adaptation of the sitting posture.
Time frame: at baseline and 12 months
Pain Visual Analogue Scale
To assess pain, the investigators will use a Visual Analog Scale (0-10).
Time frame: at baseline and 12 months
Pressure ulcer topography (stage and location )
International NPUAP/EPUAP Pressure injury classification system
Time frame: at baseline and 12 months
Comfort perception scale (Visual Analogue Scale)
Visual Analog Scale (0-10) will be used to assess comfort of patients.
Time frame: at baseline and 12 months
Postural stability perception scale (in antero-posterior and lateral stability)
self-questionnaire will be used.
Time frame: at baseline and 12 months
adverse event
Semi-structured interview following the identification of an adverse event in wheelchair by the user, within 12 months after inclusion. explain or understand the identification or not of an adverse event in wheelchair and its escalation to the clinical team, by the user.
Time frame: through study completion, an average of 12 month
Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.
Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's planned 36 months is close to that.
Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →